← All verdicts
Verdict

Data Unavailable

Every analyzed stock in Data Unavailable — 2,921 companies. Each card shows price, our model's intrinsic value (IV), and how far price sits above or below it. Click any card for the full analysis. This is a research-triage view, not a buy/sell signal.

Educational use only — not investment advice. "Undervalued / fairly valued / overvalued" and every risk score reflect our models vs. price, which can be wrong or based on stale or incomplete data. Always review the company's own financials and SEC filings, and consult a licensed advisor, before acting.
"Data Unavailable" by: Model value (price vs DCF) Owner-earnings return (equity bond)

This lens: price against our probability-weighted DCF value (P/IV). Its own forward record began accruing on 2026-09-10 (daily snapshots); until a year of it exists, the panel below tests the nearest cousin we can measure point-in-time — cheap on book value — and says so.

Market state today: Calm — the S&P 500 closed 3.1% below its 1-year high (as of 2026-09-16). Our rule, the same one used to split every backtest on this site: sell-off = 10% or more below the 1-year high, borderline from 5%, calm otherwise. A further 7.2% fall from here would put us in a sell-off. Since 2006 the market has been in a sell-off 16.6% of the time, across 13 episodes (red bands).
2007200920112013201520172019202120232025
S&P 500 (SPY, adjusted) distance from its trailing 1-year high, weekly. Amber band: borderline (−5% to −10%). Red band: sell-off (below −10%). The dot is today. History to 2026-08-19 from the research database; today from the live feed.
Backtest · point in time · 8,702 entries in the study

Does this screen work? The record for exactly these filters

Screen tested: Proxy: price-to-book ≤ 1.2 (undervalued band has no point-in-time history yet) · bought the day of the annual report, held 12 months
Probable Buy every company that met this screen on the day it filed its annual report, hold 12 months: on average it beat the S&P 500 by +12.6 pts (1,427 entries, 311 companies, very unlikely to be luck). 50% of entries beat the S&P; 25% beat it by 30 points or more; 30% trailed it by 20 points or more. Owning everything instead averaged +1.7 pts, so the screen's edge is +10.9 pts.
+12.6 ptsvs S&P, average
50%beat the S&P
25%up 30+ pts vs S&P
30%down 20+ pts vs S&P
+14.0 ptsvs small caps, 12 mo
−15.1 pts 2019worst year to buy ?
6.1luck check ?
Does the holding period matter?3 mo: +2.3 pts 49% beat6 mo: +4.6 pts 49% beat12 mo: +12.6 pts 50% beat24 mo: +21.8 pts 46% beat3 yr, per yr: +1.3 pts 40% beat
Market state at entryCompany-yearsvs S&P 12 movs small caps
Calm ◀ today1,245+7.9 pts t 4.6+10.1 pts
Sell-off (S&P ≥10% off high)182+44.5 pts t 4.0+40.7 pts
Sector (SEC group)nvs S&P 12 mo3 yrs / yr
Industrials & manufacturing466+13.0 pts t 4.0−2.2 pts
Energy126+7.4 pts t 1.2−7.8 pts
Other115+8.4 pts t 1.8+3.8 pts
Tech hardware & semis113+10.9 pts t 1.6+2.3 pts
Services96+11.9 pts t 2.7+12.2 pts
Retail & consumer87+17.2 pts t 2.1+10.2 pts
Finance & real estate72−1.7 pts t -0.5−2.4 pts
Utilities65+5.6 pts t 0.6−1.2 pts
Construction53+13.2 pts t 1.7−2.4 pts
Biotech & pharma44+47.1 pts t 1.6+10.0 pts
Telecom & media43+14.0 pts t 0.7−6.3 pts
Software & IT services35+39.9 pts t 1.8+1.2 pts

Holds up out of sample? Before 2018: +10.7 pts (n 629, t 6.0). From 2018: +14.0 pts (n 798, t 4.1). Same sign in both halves.

Year2010201120122013201420152016201720182019202020212022202320242025
vs S&P+13 pts+5 pts+14 pts+18 pts−4 pts−4 pts+22 pts+12 pts−3 pts−15 pts+87 pts+8 pts+17 pts−9 pts−7 pts+15 pts
n254310610178841118178991297276108121115

Read the research behind this screen: Price-to-book still sorts, across all sizes → · Test your own combination in the Screen Lab →

Our model values are recomputed daily but were never stored historically, so this band cannot be backtested honestly yet. Daily snapshots began 2026-09-10; a true record accrues from there. Until then the nearest tested cousin is shown — cheap on book value — and labelled as a proxy. Point-in-time: each entry is one company bought at the first close after its 10-K filing date, using only filings available that day, held 12 months; result = total return minus SPY over the same months (vs IWM for 12 months; 3-yr annualised). Survivorship-tilted universe; no costs; read spreads, not levels. Educational, hypothetical, before costs.

Sort by: A–Z Riskiest Most overvalued Most shorted Buyers' strike Largest
SEI
Solaris Energy Infrastructure, Inc.
Valuation N/A
Industrials Risk 51 · Elevated
Price$61.11
Model IV—
P/IV—
Limited data — see page
SER
Serina Therapeutics, Inc.
Valuation N/A
Healthcare Risk 27 · Moderate
Price$2.22
Model IV—
P/IV—
Market implies +85.0%/yr vs model +2.0% · above model
SERA
SERA PROGNOSTICS, INC.
Valuation N/A
Healthcare Risk 31 · Moderate
Price$2.03
Model IV—
P/IV—
Market implies +116.1%/yr vs model +2.0% · above model
SERV
Serve Robotics Inc. /DE/
Valuation N/A
Industrials Risk 44 · Elevated
Price$4.48
Model IV—
P/IV—
Market implies +83.4%/yr vs model +15.0% · above model
SES
SES AI Corp
Valuation N/A
Technology Risk 44 · Elevated
Price$0.53
Model IV—
P/IV—
Market implies +43.4%/yr vs model +15.0% · above model
SEV
Aptera Motors Corp
Valuation N/A
Consumer Cyclical Risk 42 · Elevated
Price$2.19
Model IV—
P/IV—
Market implies +43.6%/yr vs model +8.0% · above model
SFHG
SAMFINE CREATION HOLDINGS GROUP Ltd
Valuation N/A
Communication Services Risk 26 · Moderate
Price$2.15
Model IV—
P/IV—
Limited data — see page
SFWL
SHENGFENG DEVELOPMENT Ltd
Valuation N/A
Industrials Risk 45 · Elevated
Price$8.38
Model IV—
P/IV—
Limited data — see page
SG
Sweetgreen, Inc.
Valuation N/A
Consumer Cyclical Risk 27 · Moderate
Price$7.10
Model IV—
P/IV—
Market implies +20.8%/yr vs model +18.9% · in line
SGHC
Super Group (SGHC) Ltd
Valuation N/A
Communication Services Risk 40 · Elevated
Price$13.84
Model IV—
P/IV—
Limited data — see page
SGHT
Sight Sciences, Inc.
Valuation N/A
Healthcare Risk 37 · Moderate
Price$8.14
Model IV—
P/IV—
Market implies +45.4%/yr vs model +12.1% · above model
SGML
Sigma Lithium Corp
Valuation N/A
Basic Materials Risk 39 · Moderate
Price$9.50
Model IV—
P/IV—
Limited data — see page
SGMT
Sagimet Biosciences Inc.
Valuation N/A
Healthcare Risk 33 · Moderate
Price$10.88
Model IV—
P/IV—
Market implies +81.2%/yr vs model +15.0% · above model
SGP
SpyGlass Pharma, Inc.
Valuation N/A
Healthcare Risk 31 · Moderate
Price$27.52
Model IV—
P/IV—
Limited data — see page
SHAZ
SharonAI Holdings Inc.
Valuation N/A
Technology Risk 42 · Elevated
Price$51.91
Model IV—
P/IV—
Market implies +80.3%/yr vs model +50.0% · above model
SHIM
Shimmick Corp
Valuation N/A
Industrials Risk 40 · Elevated
Price$3.44
Model IV—
P/IV—
Limited data — see page
SHMD
SCHMID Group N.V.
Valuation N/A
Industrials Risk 32 · Moderate
Price$3.38
Model IV—
P/IV—
Limited data — see page
SHMDW
SCHMID Group N.V.
Valuation N/A
Industrials Risk 32 · Moderate
Price$0.78
Model IV—
P/IV—
Limited data — see page
SHPH
Shuttle Pharmaceuticals Holdings, Inc.
Valuation N/A
Healthcare Risk 27 · Moderate
Price$3.53
Model IV—
P/IV—
Limited data — see page
SID
NATIONAL STEEL CO
Valuation N/A
Basic Materials Risk 51 · Elevated
Price$1.27
Model IV—
P/IV—
Market implies +111.3%/yr vs model +0.0% · above model
SIDU
Sidus Space Inc.
Valuation N/A
Communication Services Risk 31 · Moderate
Price$1.96
Model IV—
P/IV—
Market implies +58.8%/yr vs model +22.5% · above model
SIFY
SIFY TECHNOLOGIES LTD
Valuation N/A
Technology Risk 36 · Moderate
Price$13.78
Model IV—
P/IV—
Limited data — see page
SII
SPROTT INC.
Valuation N/A
Financial Services Risk 35 · Moderate
Price$131.68
Model IV—
P/IV—
Limited data — see page
SILO
Silo Pharma, Inc.
Valuation N/A
Healthcare Risk 37 · Moderate
Price$2.10
Model IV—
P/IV—
Market implies +83.2%/yr vs model +15.0% · above model
SIM
GRUPO SIMEC, S.A.B. de C.V.
Valuation N/A
Basic Materials Risk 36 · Moderate
Price$26.40
Model IV—
P/IV—
Limited data — see page
SIMA
SIM Acquisition Corp. I
Valuation N/A
Financial Services
Price$11.15
Model IV—
P/IV—
Limited data — see page
SIMAU
SIM Acquisition Corp. I
Valuation N/A
Financial Services
Price$11.25
Model IV—
P/IV—
Limited data — see page
SIMAW
SIM Acquisition Corp. I
Valuation N/A
Financial Services
Price$0.15
Model IV—
P/IV—
Limited data — see page
SIMO
Silicon Motion Technology CORP
Valuation N/A
Technology Risk 56 · Elevated
Price$239.20
Model IV—
P/IV—
Market implies +61.0%/yr vs model +2.0% · above model
SINT
Sintx Technologies, Inc.
Valuation N/A
Healthcare Risk 31 · Moderate
Price$1.80
Model IV—
P/IV—
Market implies +29.1%/yr vs model +13.9% · above model
SION
Sionna Therapeutics, Inc.
Valuation N/A
Healthcare Risk 34 · Moderate
Price$7.85
Model IV—
P/IV—
Limited data — see page
SITM
SITIME Corp
Valuation N/A
Technology Risk 46 · Elevated
Price$635.66
Model IV—
P/IV—
Market implies +77.8%/yr vs model +10.5% · above model
SJT
SAN JUAN BASIN ROYALTY TRUST
Valuation N/A
Financial Services
Price$3.20
Model IV—
P/IV—
Limited data — see page
SKBL
Skyline Builders Group Holding Ltd
Valuation N/A
Industrials
Price$2.37
Model IV—
P/IV—
Market implies +24.4%/yr vs model +2.0% · above model
SKE
Skeena Resources Ltd
Valuation N/A
Basic Materials Risk 51 · Elevated
Price$31.72
Model IV—
P/IV—
Limited data — see page
SKM
SK TELECOM CO LTD
Valuation N/A
Communication Services Risk 35 · Moderate
Price$36.32
Model IV—
P/IV—
Limited data — see page
SKYE
Skye Bioscience, Inc.
Valuation N/A
Healthcare Risk 31 · Moderate
Price$2.04
Model IV—
P/IV—
Limited data — see page
SKYH
Sky Harbour Group Corp
Valuation N/A
Real Estate Risk 46 · Elevated
Price$10.14
Model IV—
P/IV—
Market implies +22.5%/yr vs model +50.0% · below model
SLAB
SILICON LABORATORIES INC.
Valuation N/A
Technology Risk 31 · Moderate
Price$220.33
Model IV—
P/IV—
Market implies +25.0%/yr vs model +2.0% · above model
SLAI
SOLAI Ltd
Valuation N/A
Financial Services Risk 31 · Moderate
Price$3.72
Model IV—
P/IV—
Market implies +100.9%/yr vs model +2.0% · above model
SLDB
Solid Biosciences Inc.
Valuation N/A
Healthcare Risk 42 · Elevated
Price$8.70
Model IV—
P/IV—
Market implies +70.7%/yr vs model +15.0% · above model
SLDP
Solid Power, Inc.
Valuation N/A
Technology Risk 43 · Elevated
Price$2.46
Model IV—
P/IV—
Market implies +36.9%/yr vs model +50.0% · below model
SLF
SUN LIFE FINANCIAL INC
Valuation N/A
Financial Services
Price$79.67
Model IV—
P/IV—
Limited data — see page
SLGL
Sol-Gel Technologies Ltd.
Valuation N/A
Healthcare Risk 40 · Elevated
Price$65.94
Model IV—
P/IV—
Market implies +32.1%/yr vs model +2.0% · above model
SLI
STANDARD LITHIUM LTD.
Valuation N/A
Basic Materials Risk 38 · Moderate
Price$2.23
Model IV—
P/IV—
Limited data — see page
SLM
SLM Corp
Valuation N/A
Financial Services Risk 41 · Elevated
Price$26.04
Model IV—
P/IV—
Limited data — see page
SLMBP
SLM Corp
Valuation N/A
Financial Services Risk 44 · Elevated
Price$74.15
Model IV—
P/IV—
Limited data — see page
SLMT
Brera Holdings PLC
Valuation N/A
Communication Services
Price$3.57
Model IV—
P/IV—
Limited data — see page
SLN
Silence Therapeutics plc
Valuation N/A
Healthcare Risk 31 · Moderate
Price$13.02
Model IV—
P/IV—
Market implies +129.4%/yr vs model +2.0% · above model
SLNH
Soluna Holdings, Inc
Valuation N/A
Financial Services Risk 35 · Moderate
Price$1.19
Model IV—
P/IV—
Market implies +27.5%/yr vs model +20.0% · above model
SLNHP
Soluna Holdings, Inc
Valuation N/A
Financial Services Risk 27 · Moderate
Price$11.33
Model IV—
P/IV—
Market implies +28.2%/yr vs model +20.0% · above model
SLRC
SLR Investment Corp.
Valuation N/A
Unknown Risk 55 · Elevated
Price$12.08
Model IV—
P/IV—
Limited data — see page
SLS
SELLAS Life Sciences Group, Inc.
Valuation N/A
Healthcare Risk 37 · Moderate
Price$11.55
Model IV—
P/IV—
Market implies +114.4%/yr vs model +15.0% · above model
SLSN
SOLESENCE, INC.
Valuation N/A
Consumer Defensive Risk 27 · Moderate
Price$0.81
Model IV—
P/IV—
Market implies +25.0%/yr vs model +20.5% · above model
SLSR
Solaris Resources Inc.
Valuation N/A
Basic Materials
Price$7.91
Model IV—
P/IV—
Limited data — see page
SLXN
Silexion Therapeutics Corp
Valuation N/A
Healthcare Risk 33 · Moderate
Price$0.39
Model IV—
P/IV—
Limited data — see page
SLXNW
Silexion Therapeutics Corp
Valuation N/A
Healthcare Risk 44 · Elevated
Price$0.01
Model IV—
P/IV—
Limited data — see page
SM
SM Energy Co
Valuation N/A
Energy Risk 43 · Elevated
Price$41.29
Model IV—
P/IV—
Market implies -21.2%/yr vs model +4.6% · below model
SMFG
SUMITOMO MITSUI FINANCIAL GROUP, INC.
Valuation N/A
Financial Services Risk 52 · Elevated
Price$27.29
Model IV—
P/IV—
Limited data — see page
SMJF
SMJ International Holdings Inc.
Valuation N/A
Industrials Risk 50 · Elevated
Price$1.07
Model IV—
P/IV—
Limited data — see page